PlainRecalls
FDA Drug Moderate Class II Terminated

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56

Reported: March 22, 2017 Initiated: February 7, 2017 #D-0517-2017

Product Description

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56

Reason for Recall

Failed Impurities/Degradation Specifications

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
7,628 HDPE bottles (228,840 tablets)
Distribution
Nationwide
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56. Recalled by Teva Pharmaceuticals USA. Units affected: 7,628 HDPE bottles (228,840 tablets).
Why was this product recalled?
Failed Impurities/Degradation Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on March 22, 2017. Severity: Moderate. Recall number: D-0517-2017.